Definition: Croup, also known as laryngotracheobronchitis, is a respiratory illness that results in inflammation and swelling of the upper airway. It is usually self-limiting, with symptom resolution within 48 hours (up to 1 week). \(^{(1)}\)

Pathophysiology: Croup is most commonly caused by Parainfluenza virus. Other causes include respiratory syncytial virus, influenza A and B, Mycoplasma pneumonia, and other respiratory viruses. \(^{(1)}\)

Inclusion Criteria \(^{(1-2)}\)
- 6 months to 6 years
- Previously healthy

Exclusion Criteria \(^{(1)}\)
- Toxic appearance
- Known upper airway abnormality (stridor at rest)
- Hypotonia
- Neuromuscular disorder

Differential Diagnosis \(^{(2)}\)
- Bacterial tracheitis
- Epiglottitis
- Foreign body
- Retropharyngeal abscess
- Hereditary angioedema
- Congenital abnormality
- Anaphylaxis
- Laryngomalacia
- Tracheomalacia

Diagnostic Evaluation \(^{(1-2)}\)
Croup occurs primarily in late fall to early winter but can occur year-round.

History: Assess for
- With or without antecedent upper respiratory symptoms of cough, rhinorrhea, fever
- Abrupt onset
- Symptoms worse at night
- Symptoms worse with agitation

Physical Examination
Complete routine vital signs including blood pressure

Assess for:
- Barky cough
- Hoarseness
- No to moderately high fever
- Irritability
- Inspiratory stridor
- Chest wall indrawing of varying severity
- Absence of drooling
- Non-toxic appearance
- Tachypnea
- Ability to talk or feed
- Retractions
- Mental status

Critical Points of Evidence*

Evidence Supports
- Administer PO dexamethasone 0.3 mg/kg to all patients with croup. If the patient is unable to tolerate oral administration, give IM dexamethasone instead. \(^{(1-2,3-17)}\) — Strong recommendation, moderate quality evidence
- Give inhaled racemic epinephrine if the patient has stridor at rest. \(^{(1-2,18-23)}\) — Strong recommendation, moderate quality evidence
- Observe the patient for 2 hours after epinephrine administration. \(^{(1-2)}\) — Strong recommendation, very low quality evidence
- Admit patients who require supplemental oxygen. \(^{(24)}\) — Strong recommendation, very low quality evidence

Evidence Against
- Do not routinely use mist therapy for the treatment of croup. \(^{(1-2,25,26)}\) — Strong recommendation, moderate quality evidence
- Do not routinely use heliox for the treatment of croup. \(^{(2,27-30)}\) — Strong recommendation with low quality evidence
- Do not routinely use viral testing or laboratory assessments. \(^{(1-2,31)}\) — Strong recommendation, very low quality evidence

Evidence Lacking/Inconclusive
- Adopt the Alberta guideline’s severity scoring guidance. \(^{(2)}\) — Consensus recommendation
- Do not routinely use chest radiographs upon initial presentation to determine diagnosis and/or level of severity. \(^{(1-2)}\) — Consensus recommendation
- Re-dose nebulized racemic epinephrine as needed every 2 hours with ongoing MD evaluation. Consider RRT/escalation of care if epinephrine is needed more frequently than every 2 hours and/or the patient has worsening hypoxia or respiratory distress. \(^{(1-2)}\) — Consensus recommendation
- Admit patients who have received ≥3 doses of racemic epinephrine, patients who are unable to tolerate PO, and patients in significant respiratory distress. \(^{(1-2,32)}\) — Consensus recommendation
- Discharge patients not meeting admission criteria and to advise parents when to return for care, i.e., patient has increasing respiratory distress and/or stridor at rest. \(^{(1-3)}\) — Consensus recommendation

*NOTE: The references cited represent the entire body of evidence reviewed to make each recommendation.
Condition-Specific Elements of Clinical Management

**Admission Criteria**
- Significant respiratory distress
- ≥3 doses of racemic epinephrine administered
- Unable to tolerate PO
- Supplemental O₂ requirement

**Discharge Criteria**
- No stridor at rest
- No significant respiratory distress
- No supplemental O₂ requirement
- No symptom recurrence 2 hours after racemic epinephrine administration

**Consults/Referrals**
Consult ENT if the patient fails to respond to the 2ⁿᵈ dose of dexamethasone or if there is increased concern for alternate diagnosis

**Measures**

**Process**
- Order set utilization rate
- Proportion of patients with a chest x-ray obtained
- Proportion of patients with any imaging study obtained
- Proportion of patients with viral studies obtained
- Median time to first dose of racemic epinephrine
- Proportion of patients receiving racemic epinephrine (EC, IP)
- Median time to first dose of dexamethasone
- Proportion of patients receiving a 2ⁿᵈ dose of dexamethasone
- Proportion of patients with an ENT consult

**Outcome**
- Inpatient length of stay
- Admission rate
- Readmission rate
**TCH Evidence-Based Outcomes Center**

**Clinical Algorithm for Croup**

**Initial clinical findings suggestive of croup**

- Begin
  - Administer PO dexamethasone (Mild)
  - Impending or actual respiratory arrest
    - Administer PO dexamethasone; consider IM route if patient unable to tolerate PO

**Mild**
- Occasional barky cough
- No audible stridor at rest
- No to mild suprasternal and/or intercostal indrawing (retractions of the skin to the chest wall)

**Moderate**
- Frequent barky cough
- Easily audible stridor at rest
- Suprasternal and sternal wall retractions at rest
- No or little distress or agitation

**Severe**
- Frequent barky cough
- Prominent inspiratory and occasionally expiratory stridor
- Marked sternal wall retractions
- Significant distress and agitation

**Discharge Criteria**
- No stridor at rest
- No significant respiratory distress
- No supplemental O₂ requirement
- No symptom recurrence 2 hours after racemic epinephrine administration

**Admission Criteria**
- Significant respiratory distress
- ≥3 doses of racemic epinephrine administered
- Unable to tolerate PO
- Supplemental O₂ requirement

**OFF Algorithm**
- Manage as appropriate to clinical findings

**No**
- Administer 2nd dose of dexamethasone
- Consider RRT/escalation of care if epinephrine is needed more frequently than every 2 hours and/or the patient has worsening hypoxia or respiratory distress.
- Consult ENT for further management

**Yes**
- Discharge home once discharge criteria are met*
  - If patient improving after 2nd dose of nebulized racemic epinephrine and discharge criteria are met, discharge home.
  - If a 3rd dose of nebulized racemic epinephrine is required, admit the patient and place IV.
  - Consider alternative diagnosis
  - Re-dose nebulized racemic epinephrine every 2 hours (or more frequently as needed with ongoing MD evaluation)
  - Provide parents with information on when to return for care

**No stridor at rest**
- Give nebulized racemic epinephrine

**Stridor at rest**
- Administer 2nd dose of dexamethasone

**Continued stridor at rest**
- Discharge home once discharge criteria are met*
  - Ensure patient is tolerating PO
  - Provide parents with information on when to return for care

**Impending or actual respiratory arrest**
- Administer PO dexamethasone (Severe)

**Discharge Criteria**
- No stridor at rest
- No significant respiratory distress
- No supplemental O₂ requirement
- No symptom recurrence 2 hours after racemic epinephrine administration

**Admission Criteria**
- Significant respiratory distress
- ≥3 doses of racemic epinephrine administered
- Unable to tolerate PO
- Supplemental O₂ requirement

**OFF Algorithm**
- Manage as appropriate to clinical findings

**No**
- Administer 2nd dose of dexamethasone
- Consider RRT/escalation of care if epinephrine is needed more frequently than every 2 hours and/or the patient has worsening hypoxia or respiratory distress.
- Consult ENT for further management

**Yes**
- Discharge home once discharge criteria are met*
  - Ensure patient is tolerating PO
  - Provide parents with information on when to return for care

**Yes**
- Discharge home after 2 hours of observation following nebulized racemic epinephrine administration, once discharge criteria are met*
  - If patient improving after 2nd dose of nebulized racemic epinephrine and discharge criteria are met, discharge home.
  - If a 3rd dose of nebulized racemic epinephrine is required, admit the patient and place IV.
  - Consider alternative diagnosis
  - Re-dose nebulized racemic epinephrine every 2 hours (or more frequently as needed with ongoing MD evaluation)
  - Provide parents with information on when to return for care

**No**
- Administer PO dexamethasone (Moderate)

**Discharge Criteria**
- No stridor at rest
- No significant respiratory distress
- No supplemental O₂ requirement
- No symptom recurrence 2 hours after racemic epinephrine administration

**Admission Criteria**
- Significant respiratory distress
- ≥3 doses of racemic epinephrine administered
- Unable to tolerate PO
- Supplemental O₂ requirement

**OFF Algorithm**
- Manage as appropriate to clinical findings

**No**
- Administer 2nd dose of dexamethasone
- Consider RRT/escalation of care if epinephrine is needed more frequently than every 2 hours and/or the patient has worsening hypoxia or respiratory distress.
- Consult ENT for further management

**Yes**
- Discharge home once discharge criteria are met*
  - Ensure patient is tolerating PO
  - Provide parents with information on when to return for care
References

8. Geelhoed, G. C., & Macdonald, W. B. (1995). Oral dexamethasone in the treatment of croup: 0.15 mg/kg versus 0.3 mg/kg versus 0.6 mg/kg. *Pediatric Pulmonology, 20*(6), 362-368.
Clinical Standards Preparation

This clinical standard was prepared by the Evidence-Based Outcomes Center (EBOC) team in collaboration with content experts at Texas Children’s Hospital. Development of this clinical standard supports the TCH Quality and Patient Safety Program initiative to promote clinical standards and outcomes that build a culture of quality and safety within the organization.

Croup Content Expert Team
Daniel Chelius, MD, Otolaryngology
Melissa Chiadek, MD, Pediatric Hospital Medicine
Jennifer Fuchs, MD, Pediatric Hospital Medicine Fellow
Lacherie Green, BSN, RN, Inpatient Nursing
Charles Hughes, MD, Otolaryngology
Anita Jimenez-Belinoski, MD, TCP
Julia Lawrence, RT, Respiratory Care
Erin McDade, PharmD, Pharmacy
Amanda Messer, MD, Pediatric Hospital Medicine Fellow
Brent Mothner, MD, Pediatric Hospital Medicine
Anriada Nassif, MD, Emergency Medicine Fellow
Sandhya Sasi, MD, Emergency Medicine
Ronisha Turner, RN, MSN, Inpatient Nursing

EBOC Team
Jennifer Loveless, MPH, Research Specialist
Charles Macias, MD, MPH, Medical Director
Ellis Arjmand, MD, MMM, PhD, Associate Director

Additional EBOC Support
Tom Burke, Research Assistant
Sherin Titus, Research Assistant
Karen Gibbs, MSN/MPH, RN, Research Specialist
Sheesha Porter, MS, RN, Research Specialist
Anne Dykes, MSN, RN, Assistant Director
Kathy Carberry, MPH, RN, Director

No relevant financial or intellectual conflicts to report.

Development Process

This clinical standard was developed using the process outlined in the EBOC Manual. The literature appraisal documents the following steps:

1. Review Preparation
   - PICO questions established
   - Evidence search confirmed with content experts

2. Review of Existing External Guidelines
   - Toward Optimized Practice (TOP; Alberta): Diagnosis and Management of Croup (January 2008), Seattle Children’s Hospital: Croup (December 2011)

3. Literature Review of Relevant Evidence
   - Searched: Pubmed, Cochrane, Google

4. Critically Analyze the Evidence
   - 4 meta-analyses, 1 systematic review, 17 randomized controlled trials, and 7 nonrandomized studies

5. Summarize the Evidence
   - Materials used in the development of the clinical standard, literature appraisal, and any order sets are maintained in a Croup evidence-based review manual within EBOC.

Evaluating the Quality of the Evidence

Published clinical guidelines were evaluated for this review using the AGREE II criteria. The summary of these guidelines are included in the literature appraisal. AGREE II criteria evaluate Guideline Scope and Purpose, Stakeholder Involvement, Rigor of Development, Clarity and Presentation, Applicability, and Editorial Independence using a 4-point Likert scale. The higher the score, the more comprehensive the guideline. This clinical standard specifically summarizes the evidence in support of or against specific interventions and identifies where evidence is lacking/inconclusive. The following categories describe how the quality of the evidence is rated and how a strong versus weak recommendation is established. The literature appraisal reflects the critical points of evidence.

Recommendation

<table>
<thead>
<tr>
<th>Quality</th>
<th>Type of Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>Consistent evidence from well-performed RCTs or exceptionally strong evidence from unbiased observational studies</td>
</tr>
<tr>
<td>Moderate</td>
<td>Evidence from RCTs with important limitations (e.g., inconsistent results, methodological flaws, indirect evidence, or imprecise results) or unusually strong evidence from unbiased observational studies</td>
</tr>
<tr>
<td>Low</td>
<td>Evidence for at least 1 critical outcome from observational studies, RCTs with serious flaws or indirect evidence</td>
</tr>
<tr>
<td>Very Low</td>
<td>Evidence for at least 1 critical outcome from unsystematic clinical observations or very indirect evidence</td>
</tr>
</tbody>
</table>

Recommendations

Practice recommendations were directed by the existing evidence and consensus amongst the content experts. Patient and family preferences were included when possible. The Content Expert Team and EBOC team remain aware of the controversies in the diagnosis/management of Croup in children. When evidence is lacking, options in care are provided in the clinical standard and the accompanying order sets (if applicable).

Approval Process

Clinical standards are reviewed and approved by hospital committees as deemed appropriate for its intended use. Clinical standards are reviewed as necessary within EBOC at Texas Children’s Hospital. Content Expert Teams are involved with every review and update.

Disclaimer

Practice recommendations are based upon the evidence available at the time the clinical standard was developed. Clinical standards (guidelines, summaries, or pathways) do not set out the standard of care and are not intended to be used to dictate a course of care. Each physician/practitioner must use his or her independent judgment in the management of any specific patient and is responsible, in consultation with the patient and/or the patient’s family, to make the ultimate judgment regarding care.

Version History

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mar 2016</td>
<td>Originally completed</td>
<td></td>
</tr>
</tbody>
</table>